Skip to main content
. 2018 Dec 14;9(98):37080–37096. doi: 10.18632/oncotarget.26354

Figure 4.

Figure 4

(A & B) Effect of different doses of niraparib on tumor volume in BRCA1mut MDA-MB-436 TNBC and BRCAwt OVC134 ovarian xenograft models. Niraparib was administered at 25, 50, and 75 mg/kg once daily for 28 days in MDA-MB-436 model (A) or at 20 and 40 mg/kg once daily, respectively, for 32 days and at 60 mg/kg once daily for 4 days and then at 50 mg/kg once daily for 28 days due to body weight loss observed in OVC134 model (B). One mouse from 40 mg/kg was excluded from final analysis due to extensive drug holiday applied to it, and 3 mice from 60 mg/kg treatment groups dead (B). (C) The correlation between percentage of TGI and doses used from Figure 4A & B and Figure 3B, 3C & 3D.